AstraZeneca (LON:AZN) has received a consensus recommendation of “Hold” from the twenty-four analysts that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a sell recommendation, six have given a hold recommendation, thirteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is GBX 5,150.15 ($73.74).

Several brokerages have weighed in on AZN. Shore Capital reissued a “hold” rating and issued a GBX 4,965 ($71.09) price target on shares of AstraZeneca in a report on Thursday. Goldman Sachs set a GBX 3,750 ($53.69) price target on AstraZeneca and gave the stock a “sell” rating in a report on Wednesday. Credit Suisse Group reissued an “outperform” rating and issued a GBX 5,800 ($83.05) price target on shares of AstraZeneca in a report on Wednesday. Jefferies Group set a GBX 5,650 ($80.90) price target on AstraZeneca and gave the stock a “buy” rating in a report on Friday, April 13th. Finally, JPMorgan Chase set a GBX 5,500 ($78.75) price target on AstraZeneca and gave the stock a “buy” rating in a report on Friday, April 13th.

Shares of LON AZN opened at GBX 4,976 ($71.25) on Friday. AstraZeneca has a fifty-two week low of GBX 4,260 ($61.00) and a fifty-two week high of GBX 5,520 ($79.04).

In related news, insider Philip A. J. Broadley purchased 415 shares of AstraZeneca stock in a transaction that occurred on Friday, February 2nd. The stock was bought at an average cost of GBX 4,846 ($69.39) per share, for a total transaction of £20,110.90 ($28,795.68).

ILLEGAL ACTIVITY WARNING: “AstraZeneca (AZN) Receives Average Rating of “Hold” from Brokerages” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/04/22/astrazeneca-azn-receives-average-rating-of-hold-from-brokerages.html.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.